Ons laatste Nieuws
Bekijk alle nieuwsberichten op farmaactueel.nl
22 sep
Burden of dose escalation with tumour necrosis factor inhibitors in rheumatoid arthritis: a systematic review of frequency and costs.
Escalating the dose of TNFi in inadequate responders in RA is widespread, occurring most frequently with infliximab and least with etanercept. This practice not only increases drug costs, but also RA-related and total costs (Clin Exp Reumatol)
Escalating the dose of TNFi in inadequate responders in RA is widespread, occurring most frequently with infliximab and least with etanercept. This practice not only increases drug costs, but also RA-related and total costs (Clin Exp Reumatol)
Blijf op de hoogte
Wilt u altijd op de hoogte blijven van de laatste veranderingen en nieuws over Farma-actueel? Vraag de nieuwsbrief aan door uw e-mailadres hieronder in te vullen.